Cheryl Smith, PhD
Neurology · Morgantown, WVNPI 1396037966
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by AstraZeneca at 39.6% of the total. 2025 is the largest year on record at $30,126, 7.7 times the $3,890 reported in 2019. Among neurology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 486 payments — averaging $140.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- UCB, Inc.$22K
- Argenx US, Inc.$8K
- Catalyst Pharmaceuticals, Inc.$4K
- AbbVie$2K
- MDD US Operations, LLC$489
- plus $5K from 46 others
Across 49 payments — averaging $6652.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$204K
- AstraZeneca$68K
- Sanofi US Services Inc.$54K
- Argenx US, Inc.$70
What the payments were for
- Consulting fees$32,87048%
- Speaking & faculty fees$17,23025%
- Travel & lodging$7,39511%
- Food & beverage$10,87316%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,436 in reported general payments places this provider in the 90th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $141,550 |
| Memantine Hcl ErMemantine Hcl | 12 | $3,332 |
| Mycophenolate Mofetil | 12 | $1,832 |
| Pyridostigmine Bromide | 18 | $1,692 |
| Memantine Hcl | 40 | $1,498 |
| Mirtazapine | 27 | $1,119 |
| Gabapentin | 44 | $619 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $568 |
| Donepezil Hcl | 46 | $510 |
| Amitriptyline Hcl | 15 | $392 |
| Phenytoin Sodium Extended | 11 | $296 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 12 | $291 |
| Levetiracetam | 11 | $246 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 13 | $175 |
| Pregabalin | 11 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga | $426 | $141,55016 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $232 | $3,52330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 neurology providers in West Virginia.
Other neurology in Morgantown
- Umer NajibMorgantown$246K
- Mouhannad AzzouzMorgantown$40K
- Maria Moreno EscobarMorgantown$23K
- Shumaila SultanMorgantown$13K
- Ann MurrayMorgantown$12K
- Violina MelnicMorgantown$12K
- Melanie WardMorgantown$9K
- Richa TripathiMorgantown$8K
- Phong VuMorgantown$5K
- Ruchi DhyaniMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.